6,4'-Dihydroxy-7-methoxyflavanoneCAS# 189689-32-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 189689-32-5 | SDF | Download SDF |
| PubChem ID | 25181514 | Appearance | Powder |
| Formula | C16H14O5 | M.Wt | 286.27 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S)-6-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one | ||
| SMILES | COC1=C(C=C2C(=O)CC(OC2=C1)C3=CC=C(C=C3)O)O | ||
| Standard InChIKey | XQZKTABHCQFBQV-AWEZNQCLSA-N | ||
| Standard InChI | InChI=1S/C16H14O5/c1-20-16-8-15-11(6-13(16)19)12(18)7-14(21-15)9-2-4-10(17)5-3-9/h2-6,8,14,17,19H,7H2,1H3/t14-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 6,4'-Dihydroxy-7-methoxyflavanone has antioxidant, anti-inflammatory and neuroprotective effects. 2. 6,4'-Dihydroxy-7-methoxyflavanone shows inhibition of osteoclasts differentiation and function, it can be a potential therapeutic molecule for osteoclastogenic bone diseases such osteoporosis, rheumatoid arthritis and periodontal diseases. |
| Targets | NF-kB | HO-1 | MAPK | JNK | PGE | TNF-α | IL Receptor | ERK |
6,4'-Dihydroxy-7-methoxyflavanone Dilution Calculator
6,4'-Dihydroxy-7-methoxyflavanone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4932 mL | 17.466 mL | 34.9321 mL | 69.8641 mL | 87.3301 mL |
| 5 mM | 0.6986 mL | 3.4932 mL | 6.9864 mL | 13.9728 mL | 17.466 mL |
| 10 mM | 0.3493 mL | 1.7466 mL | 3.4932 mL | 6.9864 mL | 8.733 mL |
| 50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.3973 mL | 1.7466 mL |
| 100 mM | 0.0349 mL | 0.1747 mL | 0.3493 mL | 0.6986 mL | 0.8733 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- trans-4-phenylbut-3-en-2-one
Catalog No.:BCN3805
CAS No.:1896-62-4
- Dihydrooroxylin A
Catalog No.:BCN3500
CAS No.:18956-18-8
- 6'-Hydroxy-7'-ethoxybergamottin
Catalog No.:BCC8306
CAS No.:
- Pinostrobin chalcone
Catalog No.:BCN1173
CAS No.:18956-15-5
- Ginsenoside F5
Catalog No.:BCN6419
CAS No.:189513-26-6
- Epothilone D
Catalog No.:BCC1554
CAS No.:189453-10-9
- Boc-Ser(tBu)-OH.DCHA
Catalog No.:BCC3445
CAS No.:18942-50-2
- Boc-D-Phe-OH
Catalog No.:BCC3433
CAS No.:18942-49-9
- Boc-Cys(pMeOBzl)-OH
Catalog No.:BCC3378
CAS No.:18942-46-6
- Chebulinic acid
Catalog No.:BCN3263
CAS No.:18942-26-2
- Triptinin B
Catalog No.:BCN6785
CAS No.:189389-05-7
- Endomorphin-1
Catalog No.:BCC1008
CAS No.:189388-22-5
- Akuammiline
Catalog No.:BCN4772
CAS No.:1897-26-3
- Ro 10-5824 dihydrochloride
Catalog No.:BCC7330
CAS No.:189744-94-3
- 8-Amino-2-methylquinoline
Catalog No.:BCC8782
CAS No.:18978-78-4
- 3-O-Feruloylquinic acid
Catalog No.:BCN3353
CAS No.:1899-29-2
- Palmitoylisopropylamide
Catalog No.:BCC7187
CAS No.:189939-61-5
- Mesopram
Catalog No.:BCC7549
CAS No.:189940-24-7
- Firocoxib
Catalog No.:BCC5498
CAS No.:189954-96-9
- N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide
Catalog No.:BCC5855
CAS No.:190078-50-3
- 7-Hydroxy-2,2-dimethylchromene
Catalog No.:BCN7784
CAS No.:19012-97-6
- Eupatoriochromene
Catalog No.:BCN1174
CAS No.:19013-03-7
- Demethoxyencecalin
Catalog No.:BCN1175
CAS No.:19013-07-1
- Spiratisanin A
Catalog No.:BCN6977
CAS No.:1902173-16-3
Involvement of heme oxygenase-1 induction in the cytoprotective and immunomodulatory activities of 6,4'-dihydroxy-7-methoxyflavanone in murine hippocampal and microglia cells.[Pubmed:22119385]
Eur J Pharmacol. 2012 Jan 15;674(2-3):153-62.
6,4'-Dihydroxy-7-methoxyflavanone (DMF), a biologically active compound, was isolated from the heartwood of Dalbergia odorifera T. Chen (Leguminosae). The present study proposed to examine the role of DMF as an anti-oxidative and anti-inflammatory heme oxygenase-1 (HO-1) inducer in mouse hippocampal HT22 cells and BV2 microglia cells. The effect of DMF on cell viability was determined by MTT assay and the effects of DMF on pro-inflammatory enzymes and cytokines were analyzed by western blot and ELISA. Parameters such as DMF induced HO-1 protein immunocontents, HO activity and mitogen-activated protein kinases (MAPK) activation were also measured. DMF increased cellular resistance to oxidative injury caused by glutamate-induced cytotoxicity in HT22 cells, via JUN N-terminal kinase (JNK) pathway dependent HO-1 expression. Furthermore, DMF suppressed the lipopolysaccharide (LPS)-induced expression of pro-inflammatory enzymes and inflammatory mediators in BV2 microglia. DMF suppressed production of nitric oxide (NO), prostaglandin E2 (PGE(2)), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), through extracellular signal-regulated kinase (ERK) pathway dependent HO-1 expression. This study indicates that DMF effectively modulates the regulation of anti-oxidative and anti-inflammatory action, via up-regulation of HO-1 in HT22 cells and BV2 microglia. These results suggest that DMF possesses therapeutic potentials against neurodegenerative diseases that are induced by oxidative stress and neuroinflammation.
6,4'-Dihydroxy-7-methoxyflavanone inhibits osteoclast differentiation and function.[Pubmed:23420617]
Biol Pharm Bull. 2013;36(5):796-801. Epub 2013 Feb 19.
6,4'-Dihydroxy-7-methoxyflavanone (DMF) is a flavonoid isolated from Heartwood Dalbergia odorifera. It has been known that DMF has antioxidant, anti-inflammatory and neuroprotective effects. DMF, however, the efficacy of bone related diseases has not been reported. In this study, we determined DMF's efficacy on osteoclasts differentiation and function using in vitro bone marrow macrophage osteoclast differentiation culture system. DMF inhibited receptor activators of nuclear factor kappa-B ligand (RANKL) induced osteoclastogenesis dose dependently. In addition, DMF decreased osteoclast function through disruption of actin ring formation and consequently suppression of the pit-forming activity of mature osteoclasts. Mechanistically, DMF inhibited RANKL-induced expression of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) and c-Fos via inhibition of mitogen activated protein kinases (MAPKs) pathway. Collectively, the inhibition of osteoclasts differentiation and function by DMF suggests that DMF can be a potential therapeutic molecule for osteoclastogenic bone diseases such osteoporosis, rheumatoid arthritis and periodontal diseases.
